In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH

• RheumIQ Weekly Quiz | RheumNow

EGPA https://t.co/zlquehIZQ6

• https://x.com/aabdogafar/status/2060010189059670338/photo/1

FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX

• FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor pr…

LRA Awards for Immune Resetting Therapies in Lupus LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0

Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx

• Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoi…

Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5

• Frontiers | Case Report: Ruxolitinib for systemic juvenile idiopathic arthritis…

Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN

Korean claims data on FX in RA (2010-2017; n = 43,677). RA had more FX (aHR 1.68), regardless of b/tsDMARD use. Seropositive had more Fx (aHR 1.19), Vertebral Fx (aHR 1.4) & hip Fx (aHR 1.55) VS seronegative RA https://t.co/5Fm3o841H7 https://t.co/V0L87JYtba

• Risk of fracture among patients with rheumatoid arthritis according to serologi…

Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE

• https://buff.ly/ZtBYIHG

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers. https://t.co/YUasxB43ZO https://t.co/tkvKh0JEui

• WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare | RheumNow

Join the global rheumatology community following RheumNow at #EULAR2026 ✔️ Trusted faculty voices ✔️ Fast, curated insights ✔️ Clinically relevant takeaways This is where rheumatology meets real-world practice. https://t.co/Hb88ZCP58P

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/tyd1efUtca https://t.co/zcY7RyX8SZ

• RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's | RheumNow